A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone

Prostate Cancer (Adenocarcinoma) Clinical Trial

Status Completed

Clinical Trial Summary

Adrenal androgens are serum biomarkers of interest that may help guide abiraterone acetate treatment, particularly at the time of progression. Biomarkers may also help identify pathways to resistance of abiraterone acetate treatment. The most practical way of approaching this question is to explore surrogate biomarkers of prostate cancer including quantification of pharmacodynamic endocrine biomarkers.

Clinical Trial Description

Goals of this study include:

• Explore which circulating endocrine markers or endocrine related markers have the best potential to predict clinical response to abiraterone acetate in CRPC patients

• Explore the utility of microRNA, circulating DNA and exosome analyses in complementing the previous objective ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Adenocarcinoma
• Prostate Cancer (Adenocarcinoma)
• Prostatic Neoplasms

• NCT number: NCT01857908
• Study type: Observational
• Source: University Health Network, Toronto
• Status: Completed
• Phase: N/A
• Start date: June 2012